We therefore decided to test this in vitro using BRAF wild-type melanoma cell lines CHL-1 and SK-MEL-23, and two MEK inhibitors, namely selumetinib, the MEK inhibitor used in the DOC-MEK clinical trial, and trametinib, the first MEK inhibitor approved by the FDA for use in clinical practice (https://www.cancer.gov/about-cancer/treatment/drugs/fda-trametinib). This evidence concerns the gene MAP2K7 and melanoma.